Evidence map›Paper›PMID 40710071›Full record

ArticleBiosensors2025

A Unified YOLOv8 Approach for Point-of-Care Diagnostics of Salivary

Youssef Amin, Paola Cecere, Pier Paolo Pompa

Abstract read
In one paragraph

Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Youssef AminIstituto Italiano di Tecnologia (IIT), Nanobiointeractions & Nanodiagnostics, Via Morego 30, 16163 Genova, Italy.ORCID 0000-0001-7550-6143
Paola CecereIstituto Italiano di Tecnologia (IIT), Nanobiointeractions & Nanodiagnostics, Via Morego 30, 16163 Genova, Italy.
Pier Paolo PompaIstituto Italiano di Tecnologia (IIT), Nanobiointeractions & Nanodiagnostics, Via Morego 30, 16163 Genova, Italy.ORCID 0000-0001-7549-0612

Funding

European Union - NextGenerationEU ECS00000035
6 · The paper itself

Abstract

Salivary α-amylase (sAA) is a widely recognized biomarker for stress and autonomic nervous system activity. However, conventional enzymatic assays used to quantify sAA are limited by time-consuming, lab-based protocols. In this study, we present a portable, AI-driven point-of-care system for automated sAA classification via colorimetric image analysis. The system integrates SCHEDA, a custom-designed imaging device providing and ensuring standardized illumination, with a deep learning pipeline optimized for mobile deployment. Two classification strategies were compared: (1) a modular YOLOv4-CNN architecture and (2) a unified YOLOv8 segmentation-classification model. The models were trained on a dataset of 1024 images representing an eight-class classification problem corresponding to distinct sAA concentrations. The results show that red-channel input significantly enhances YOLOv4-CNN performance, achieving 93.5% accuracy compared to 88% with full RGB images. The YOLOv8 model further outperformed both approaches, reaching 96.5% accuracy while simplifying the pipeline and enabling real-time, on-device inference. The system was deployed and validated on a smartphone, demonstrating consistent results in live tests. This work highlights a robust, low-cost platform capable of delivering fast, reliable, and scalable salivary diagnostics for mobile health applications.

Indexed as

Biosensing TechniquesPoint-of-Care SystemsSalivaSalivary alpha-AmylasesColorimetryHumansSmartphoneSalivary alpha-Amylasesconvolutional neural networks (CNNs)edge computingimage segmentationmachine learningobject detectionpoint-of-care testingYOLOv8α-Amylase

Identifiers

PMID40710071
PMCPMC12293979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.